OakLabs goal is to support scientific companies and institutions with groundbreaking revelations, perhaps most notably in the realm of drug development, companion diagnostics (CDx), support of translational medicine studies and development of IEC 62304 compliant medical device software.
The skilled team of quantum physicists and biochemists at OakLabs has developed a new approach to drug development which replaces single biomarkers with a biomarker signature: Multiple molecules are combined in a mathematical model. This enables a new era of reliability in accurately predicting (non-)responders for specific drugs, thus enabling a precision medicine approach. Not only does this lead to success in clinical trials, it can also help to gain market shares in a competitive environment, offering tangible results for continued market success after approval.
OakLabs was founded in 2011 by Martina Schad, Ph.D., and Jim
Kallarackal, Ph.D. Currently, the company has offices in Hennigsdorf/Berlin, Germany and Boston, USA.